Exacerbations of multiple sclerosis in patients treated with gamma interferon (Q40797798)

23 September 2017

Exacerbations of multiple sclerosis in patients treated with gamma interferon (English)

1 reference

23 September 2017

0 references

H S Panitch

1

1 reference

23 September 2017

R L Hirsch

series ordinal

2

1 reference

23 September 2017

A S Haley

series ordinal

3

1 reference

23 September 2017

K P Johnson

series ordinal

4

1 reference

23 September 2017

language of work or name

English

0 references

publication date

1 April 1987

1 reference

23 September 2017

1 reference

23 September 2017

1

1 reference

23 September 2017

8538

1 reference

23 September 2017

893-895

1 reference

Multiple sclerosis (second of two parts).

23 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2887%2992863-7

7 January 2021

Multiple Sclerosis as a Disease of Immune Regulation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2887%2992863-7

7 January 2021

Systemic alpha-interferon therapy of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2887%2992863-7

7 January 2021

Intrathecal Interferon Reduces Exacerbations of Multiple Sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2887%2992863-7

7 January 2021

Multicentre double-blind study of effect of intrathecally administered natural human fibroblast interferon on exacerbations of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2887%2992863-7

7 January 2021

Interferon responses of leukocytes in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2887%2992863-7

7 January 2021

Interferon production and natural killer (NK) activity in leukocyte cultures from multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2887%2992863-7

7 January 2021

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2887%2992863-7

7 January 2021

A neurologic rating scale (NRS) for use in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2887%2992863-7

7 January 2021

Distribution of alpha interferon in serum and cerebrospinal fluid after systemic administration.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2887%2992863-7

7 January 2021

Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2887%2992863-7

7 January 2021

Ia expression by vascular endothelium is inducible by activated T cells and by human gamma interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2887%2992863-7

7 January 2021

Multiple sclerosis. Evidence for antigen presentation in situ by endothelial cells and astrocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2887%2992863-7

7 January 2021

Anti I-A antibody suppresses active encephalomyelitis: treatment model for diseases linked to IR genes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2887%2992863-7

7 January 2021

Contrasting effect of alpha/beta- and gamma-interferons on expression of macrophage Ia antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2887%2992863-7

7 January 2021

10.1016/S0140-6736(87)92863-7

Identifiers

DOI

1 reference

23 September 2017

1 reference